Study Design
DesignRandomized, double-blind, placebo-controlled
Randomization1:1:1
BlindingDouble-blind
Enrollment766
Duration76 weeks
Treatment Arms
Ustekinumab 45mg 45mg SC at Wk 0,4 then q12w n=255
Ustekinumab 90mg 90mg SC at Wk 0,4 then q12w n=256
Placebo Placebo n=255
[{"id":"pasi75-w12","name":"PASI 75 at Week 12","type":"PRIMARY","unit":"%","results":[{"value":67.1,"arm_id":"ust45-arm","p_value":0.001},{"value":66.4,"arm_id":"ust90-arm","p_value":0.001},{"value":3.1,"arm_id":"pbo-arm"}],"timepoint":"Week 12","description":"Original pivotal endpoint. Note: PASI 75 (not 90 or 100) was the standard endpoint in 2009."}]